Exploring Collaboration Between Medical Information, Pharmacovigilance, and Regulatory Affairs in Drug Safety
In today's fast-evolving pharmaceutical landscape, effective collaboration among Medical Information (MI), Pharmacovigilance (PV), and Regulatory Affairs (RA) is crucial for ensuring drug safety and compliance. A complimentary upcoming webinar hosted by Xtalks aims to shed light on these interconnections and provide actionable insights for professionals in the field. This event will delve into how these departments can work harmoniously throughout the product lifecycle, from the initial detection of safety signals to the final stages of labeling and external communication.
During the session, participants will learn from industry experts about strategies to effectively escalate safety signals across different functions and maintain consistency in regulatory documents, particularly when responding to crises. The emphasis will be on avoiding common pitfalls that can occur in cross-functional communication and decision-making during critical situations. By identifying these challenges, organizations can better prepare for, and navigate through, high-pressure scenarios that involve product safety.
Notably, the webinar will explore how advancements in artificial intelligence (AI) and automation are transforming the workflows of MI, PV, and RA. These technologies offer significant advantages, such as improved signal detection, streamlined communications, and enhanced labeling practices. However, participants will also discuss the governance frameworks needed to responsibly implement AI technologies in their organizations.
The speakers at the webinar include notable practitioners from the industry, each bringing a wealth of experience and knowledge to the conversation. Moderated by Alessandra Grossi, Director of Medical Operations at TransPerfect Life Sciences, the panel includes Elke Blaetz, an experienced Senior Director in Medical Information, Ana Filipa Sousa, an Associate Director leading Medical Affairs in the UK and Ireland, and Dr. Kunvar Harsh Upveja, a global leader in Oncology and Bone Health at Biocon Biologics. Together, they will provide participants with insights on how to build stronger partnerships among MI, PV, and RA, navigate complex escalations, and prepare for the next stages of collaboration.
The event is designed for professionals across the pharmaceutical, biotech, and healthcare sectors, who seek to enhance their understanding of the roles MI, PV, and RA play in drug safety and communications. The discussion will cover the critical touchpoints defining effective collaboration strategies, including how inquiries about potential adverse events can be escalated from MI to PV and how RA ensures labeling reflects evolving safety data.
In conclusion, this webinar is an invaluable opportunity for attendees to gain practical knowledge on fostering interdepartmental partnerships, improving safety signal escalation processes, and navigating the complexities of regulatory compliance. Register now to learn from the experts and position your organization for success in the intricate world of drug development and safety management.
During the session, participants will learn from industry experts about strategies to effectively escalate safety signals across different functions and maintain consistency in regulatory documents, particularly when responding to crises. The emphasis will be on avoiding common pitfalls that can occur in cross-functional communication and decision-making during critical situations. By identifying these challenges, organizations can better prepare for, and navigate through, high-pressure scenarios that involve product safety.
Notably, the webinar will explore how advancements in artificial intelligence (AI) and automation are transforming the workflows of MI, PV, and RA. These technologies offer significant advantages, such as improved signal detection, streamlined communications, and enhanced labeling practices. However, participants will also discuss the governance frameworks needed to responsibly implement AI technologies in their organizations.
The speakers at the webinar include notable practitioners from the industry, each bringing a wealth of experience and knowledge to the conversation. Moderated by Alessandra Grossi, Director of Medical Operations at TransPerfect Life Sciences, the panel includes Elke Blaetz, an experienced Senior Director in Medical Information, Ana Filipa Sousa, an Associate Director leading Medical Affairs in the UK and Ireland, and Dr. Kunvar Harsh Upveja, a global leader in Oncology and Bone Health at Biocon Biologics. Together, they will provide participants with insights on how to build stronger partnerships among MI, PV, and RA, navigate complex escalations, and prepare for the next stages of collaboration.
The event is designed for professionals across the pharmaceutical, biotech, and healthcare sectors, who seek to enhance their understanding of the roles MI, PV, and RA play in drug safety and communications. The discussion will cover the critical touchpoints defining effective collaboration strategies, including how inquiries about potential adverse events can be escalated from MI to PV and how RA ensures labeling reflects evolving safety data.
In conclusion, this webinar is an invaluable opportunity for attendees to gain practical knowledge on fostering interdepartmental partnerships, improving safety signal escalation processes, and navigating the complexities of regulatory compliance. Register now to learn from the experts and position your organization for success in the intricate world of drug development and safety management.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.